Mirum Pharmaceuticals CEO and Leadership

Chris is an Entrepreneur-in-Residence on the Frazier Life Sciences team and an experienced business leader in therapeutic development and commercialization. Chris joined Frazier in May 2017 as founder of Flashlight Therapeutics, a search company focused on in-licensing and developing therapeutics. Chris previously served as Chief Financial Officer and Head of Corporate Development at Frazier portfolio company Tobira Therapeutics, a leading developer of therapeutics for non-alcoholic steatohepatitis. While at Tobira, Chris led the company's efforts to become a public company, expand its pipeline through partnership and in-licensing, and sell the company to Allergan for total consideration of up to $1.7 billion. Prior to Tobira, Chris held business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals and Abgenix. Chris holds a B.S.B.A. from Washington University in St. Louis and an M.B.A. from the Stanford Graduate School of Business.

Seasoned strategic communications and investor relations professional with a unique background of financial, scientific and technology expertise. Proven ability to design and execute corporate communications campaigns in local, national and global markets. Career spanning FTSE100 companies, high-tech life science growth companies and agencies. Strong team leader with proven project management and interpersonal skills.Specialties: • Investor Relations• Corporate and Product PR• Crisis Communications• Media & Analyst Relations• Strong Writer and Editor• Strategic Analysis and Planning• Marketing Leadership• Team Management• Financial Management• Accomplished Company Spokesperson• Web Communications Strategy• Marketing Communications and Program Design

Ms. Longpre joined the Company in April 2008 as a clinical consultant and became chief operating officer in June 2010. She has over 19 years of drug development and operations experience in leadership and senior roles in biotechnology and contract research organizations (CROs). She has wide-ranging experience in strategic planning, project management and all phases of clinical development including direct management of several global pivotal trials. Prior to Jennerex, she was senior vice-president, clinical and corporate development at MedGenesis Therapeutix. \ Ms. Longpre has also held senior management positions of increasing responsibility at PRA International, a global CRO, including vice president of proposals and contracts, vice president of quality and process management, director of global regulatory affairs, and director of operations during which time she was responsible for global clinical programs in several therapeutic areas. Ms. Longpre holds an MSc in medical science from Harvard Medical School, an MBA from Queens University Executive Program, and a BA from Cornell University.

Chris is an Entrepreneur-in-Residence on the Frazier Life Sciences team and an experienced business leader in therapeutic development and commercialization. Chris joined Frazier in May 2017 as founder of Flashlight Therapeutics, a search company focused on in-licensing and developing therapeutics. Chris previously served as Chief Financial Officer and Head of Corporate Development at Frazier portfolio company Tobira Therapeutics, a leading developer of therapeutics for non-alcoholic steatohepatitis. While at Tobira, Chris led the company's efforts to become a public company, expand its pipeline through partnership and in-licensing, and sell the company to Allergan for total consideration of up to $1.7 billion. Prior to Tobira, Chris held business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals and Abgenix. Chris holds a B.S.B.A. from Washington University in St. Louis and an M.B.A. from the Stanford Graduate School of Business.

Chris is an Entrepreneur-in-Residence on the Frazier Life Sciences team and an experienced business leader in therapeutic development and commercialization. Chris joined Frazier in May 2017 as founder of Flashlight Therapeutics, a search company focused on in-licensing and developing therapeutics. Chris previously served as Chief Financial Officer and Head of Corporate Development at Frazier portfolio company Tobira Therapeutics, a leading developer of therapeutics for non-alcoholic steatohepatitis. While at Tobira, Chris led the company's efforts to become a public company, expand its pipeline through partnership and in-licensing, and sell the company to Allergan for total consideration of up to $1.7 billion. Prior to Tobira, Chris held business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals and Abgenix. Chris holds a B.S.B.A. from Washington University in St. Louis and an M.B.A. from the Stanford Graduate School of Business.